Trial Profile
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary) ; XL 888 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 20 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 30 Sep 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 26 Apr 2022 Planned End Date changed from 1 Apr 2022 to 1 Oct 2022.